selected scholarly activity
-
chapters
- Acquired Bleeding Diatheses. 161-172. 2007
- Haemophilia A and Haemophilia B. 1-92. 2007
- Miscellaneous Questions. 173-191. 2007
- Management of Venous Thromboembolism. 912-924. 2005
- Joint Surgery in Patients with Inhibitors. 56-62. 2003
-
conferences
- Updated Protocol for the Phase 3, Randomized, Double-Blinded Lex-210 Study of Four-Factor Prothrombin Complex Concentrate in Patients with Acute Major Bleeding on Factor Xa Inhibitor Therapy. Blood. 1256-1256. 2023
- Use and Outcomes of Secondary Anticoagulation in Patients <21 Years Old Following Completion of a Primary Course of Anticoagulation for Treatment of Acute Provoked VTE: Findings from the Multinational Kids-DOTT Trial. Blood. 1275-1275. 2023
- Performance of D-Dimers in Patients with Prior History of Venous Thromboembolism Based on Anticoagulation Status. Blood. 8524-8525. 2022
- Risk of Recurrence after Stopping Anticoagulants in Women with Combined Oral Contraceptive-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis. Blood. 776-776. 2021
- Apixaban Versus Dalteparin for Thromboprophylaxis in Patients with Acute Spinal Cord Injury: A Pilot Study. Blood. 2434-2434. 2019
- Venous Thromboembolism in Lower Extremity Amputees: A Systematic Review of the Literature. Blood. 4980-4980. 2019
- Reasons for Switching from Warfarin to a Direct Oral Anticoagulant: A Retrospective Study. Blood. 5060-5060. 2018
- CHARACTERIZATION OF 6,122 PATIENTS WITH ACUTE VENOUS THROMBOEMBOLISM IN ROUTINE CLINICAL PRACTICE: RE-COVERY DVT/PETM PROSPECTIVE GLOBAL COHORT STUDY. Journal of the American College of Cardiology. A2109-A2109. 2018
- Anticoagulant Re-Initiation Following Intracranial Hemorrhage in Non-Valvular Atrial Fibrillation: Practices and Perceptions of Thrombosis Experts, Neurologists and Neurosurgeons. Haemophilia. 47-48. 2017
- Do Genetic Contributors to Warfarin Responsiveness or Common Thrombophilias Influence the Risk of Major Bleeding in Patients on Extended Duration Vitamin K Antagonist (VKA) for Venous Thromboembolic Disease?. Blood. 272-272. 2016
- Prediction of Bleeding Risk in Patients on Extended Oral Anticoagulation for Venous Thromboembolism. Blood. 139-139. 2016
- Warfarin Resumption after Intracranial Hemorrhage: A Systematic Review and Meta-Analysis. Blood. 3821-3821. 2016
- Incidence and risk factors for venous thromboembolism in patients with acute spinal cord injury: A retrospective study. Thrombosis Research. 97-101. 2016
- PREDICTORS OF MAJOR BLEEDING DURING WARFARIN INTERRUPTION FOR INVASIVE PROCEDURES: ANALYSIS OF THE BRIDGE TRIAL. American Journal of Hematology. E391-E391. 2016
- Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation. European Heart Journal. 440-440. 2016
- Reversal strategies and outcomes of major bleeding associated with direct oral anticoagulants compared to warfarin in routine practice: interim results from a multi-centre all-comer cohort. European Heart Journal. 1008-1008. 2016
- Efficacy and safety of dabigatran vs. warfarin for the treatment of acute venous thromboembolism: a pooled analysis of 90-day data from RE-COVER (TM) and RE-COVER (TM) II. Journal of Thrombosis and Haemostasis. 27-28. 2016
- Safety and efficacy of dabigatran compared with warfarin in patients with acute venous thromboembolism enrolled in RE-COVER (R)/RE-COVER II (TM) in Western Europe. Journal of Thrombosis and Haemostasis. 27-27. 2016
- Warfarin dose assessment every 4 weeks vs. every 6 to 8 weeks in patients with stable international normalized ratios: a retrospective study. Journal of Thrombosis and Haemostasis. 33-33. 2016
- Long Term Outcome of Splanchnic Vein Thrombosis in Cirrhosis. Journal of Hepatology. S168-S168. 2016
- Dabigatran Etexilate or Warfarin in the Treatment of Acute Venous Thromboembolism in Western European Patients: A Pooled Analysis of RE-COVER (R) and RE-COVER II (TM). Blood. 2015
- Adherence to anticoagulant treatment with apixaban and rivaroxaban in a real-world setting. European Heart Journal. 544-545. 2015
- A Cross-sectional registry on the incidence of gastrointestinal associated symptoms with pradaxa use (Gasp Registry). Journal of Thrombosis and Haemostasis. 92-92. 2015
- A global prospective cohort study of dabigatran for the treatment of venous thromboembolism (re-covery). Journal of Thrombosis and Haemostasis. 729-729. 2015
- Accuracy of three clinical prediction tools for major bleeding in patients on extended oral anticoagulant for venous thromboembolism. Journal of Thrombosis and Haemostasis. 27-27. 2015
- Adherence to anticoagulant treatment with dabigatran and rivaroxaban in a real-world setting. Journal of Thrombosis and Haemostasis. 117-117. 2015
- Antithrombotic treatment and outcomes of cirrhotic patients with splanchnic vein thrombosis: a sub-study from the ISTH registry. Journal of Thrombosis and Haemostasis. 69-70. 2015
- Antithrombotic treatment and outcomes of non-malignant non-cirrhotic splanchnic vein thrombosis: a sub-analysis from the isth registry. Journal of Thrombosis and Haemostasis. 728-729. 2015
- Bridging anticoagulation in patients who require temporary interruption of warfarin therapy for an elective invasive procedure or surgery (the bridge trial). Journal of Thrombosis and Haemostasis. 83-84. 2015
- Characteristics and reversal strategies of real-world anticoagulation-related hemorrhage in the non-vitamin K antagonist oral anticoagulant era: preliminary data from a multicentre chart review. Journal of Thrombosis and Haemostasis. 171-171. 2015
- Dabigatran and rivaroxaban adherence study- real world experience in different clinics and extended follow up (dariva study). Journal of Thrombosis and Haemostasis. 636-636. 2015
- Dabigatran or warfarin in the treatment of acute venous thromboembolism in antiphospholipid syndrome. Journal of Thrombosis and Haemostasis. 985-985. 2015
- Direct Oral Anticoagulants in the Real World: Insights into Canadian Health Care Providers’ Understanding of Medication Dosing and Use. Journal of Thrombosis and Haemostasis. 638-638. 2015
- Direct-acting oral anticoagulants in the real world: insights into appropriate prescribing and medication use. Journal of Thrombosis and Haemostasis. 91-91. 2015
- Feasibility of comparing intermittent pneumatic compression vs. a novel device for prevention of venous thromboembolism in trauma patients with contraindication to anticoagulation. Journal of Thrombosis and Haemostasis. 726-726. 2015
- Hemizygous deletion of 7Q11.21-Q11.23 eliminating VKORC1L1 does not impair blood coagulation but reveals accumulation of menaquinone-4. Journal of Thrombosis and Haemostasis. 492-492. 2015
- Natural history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: findings from the ISTH registry. Journal of Thrombosis and Haemostasis. 484-485. 2015
- Net clinical benefit of dabigatran versus warfarin in prevention of recurrent venous thromboembolism: a pooled analysis of re-cover and re-cover II. Journal of Thrombosis and Haemostasis. 644-645. 2015
- No beneficial effect of statins in reducing recurrent disease in a meta-analysis of 21,587 patients with acute symptomatic venous thromboembolism treated in phase 3 trials comparing direct oral anticoagulants with vitamin K antagonists. Journal of Thrombosis and Haemostasis. 242-242. 2015
- Noacs in venous thromboembolism - strengths and caveats. Journal of Thrombosis and Haemostasis. 35-35. 2015
- Optimal timing of warfarin resumption after warfarin related upper gastrointestinal bleeding. Journal of Thrombosis and Haemostasis. 120-120. 2015
- Perioperative management of dabigatran: a prospective cohort study. Journal of Thrombosis and Haemostasis. 203-203. 2015
- Strategies and outcomes of periprocedural bridging therapy with low-molecular-weight-heparin in patients with mechanical heart valves. Journal of Thrombosis and Haemostasis. 370-370. 2015
- Antithrombotic Treatment and Outcomes of Splanchnic Vein Thrombosis in an International Prospective Registry: Results of 2-Year Follow-up. Blood. 2014
- Influence of Age and Renal Function on Efficacy and Safety of Dabigatran Versus Warfarin for the Treatment of Acute Venous Thromboembolism: A Pooled Analysis of RE-COVER™ and RE-COVER™ II. Blood. 594-594. 2014
- Influence of Thrombophilia on the Efficacy of Dabigatran Versus Warfarin for the Extended Treatment of Acute Venous Thromboembolism in RE-MEDY. Blood. 2014
- Low Dose Oral Vitamin K Does Not Increase Time in Therapeutic Range: Results of a Multicentre Clinical Trial. Blood. 2872-2872. 2014
- Pilot/Feasibility Metrics, Real-Time Remote Monitoring, and Inter-Observer Agreement on Veno-Occlusion in a National Multicenter Randomized Controlled Trial of Pediatric Venous Thromboembolism: Findings from the Pilot/Feasibility Phase of the Kids-DOTT Trial. Blood. 2014
- Post-Hoc Analysis of RE-MEDY (TM) Demonstrates Significant Real-World Net Clinical Benefit for Dabigatran Versus Warfarin in Prevention of Secondary Venous Thromboembolism. Blood. 2014
- Efficacy of Dabigatran versus Warfarin in Patients With Acute Venous Thromboembolism and Thrombophilia: A Pooled Analysis of RE-COVER™ and RE-COVERTM II. Circulation. 2014
- Treatment of acute pulmonary embolism with dabigatran or warfarin: a pooled analysis of efficacy data from RE-COVER and RE-COVER II. European Heart Journal. 990-990. 2014
- Major bleeding events with dabigatran versus warfarin in patients with acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis. 62-63. 2014
- Vitamin K antagonists vs. heparin for the treatment of splanchnic vein thrombosis in the isth registry: results of 12-month follow-up and a propensity score analysis. Journal of Thrombosis and Haemostasis. 8-9. 2014
- Influence of cancer on the efficacy and safety of dabigatran vs. warfarin for the acute and extended treatment of venous thromboembolism. Thrombosis Research. S221-S221. 2014
- Inflammation Markers and The Risk Of Post Thrombotic Syndrome: Results From The Bio-Sox Study. Blood. 36-36. 2013
- Influence Of Active Cancer On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II. Blood. 582-582. 2013
- Influence Of Age On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis Of RE-Cover and RE-Cover II. Blood. 2375-2375. 2013
- Influence Of Concomitant NSAID Or ASA On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II. Blood. 1136-1136. 2013
- Influence Of Renal Function On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II. Blood. 212-212. 2013
- Perioperative Management Of Patients On Dabigatran – a Prospective Cohort Study. Blood. 3637-3637. 2013
- Predictors Of The Post-Thrombotic Syndrome In a Large Cohort Of Patients With Proximal DVT: Secondary Analysis Of The Sox Trial. Blood. 460-460. 2013
- The Effectiveness Of 30-40 Mm Hg Compression Stockings To Treat Acute Leg Pain Associated With Proximal Deep Vein Thrombosis: Results From The Sox Randomized Controlled Trial. Blood. 1126-1126. 2013
- Efficacy and Safety of Different Bridging Regimens of Parenteral Anticoagulation After Mechanical Valve Replacement. Canadian Journal of Cardiology. S348-S349. 2013
- Safety and Efficacy of Dabigatran Compared to Warfarin for Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: a Meta-Analysis. Canadian Journal of Cardiology. S100-S100. 2013
- Efficacy and safety of different bridging regimens of parenteral anticoagulation after mechanical valve replacement. European Heart Journal. 814-814. 2013
- Adherence to anticoagulant treatment with dabigatran in a real-world setting. Journal of Thrombosis and Haemostasis. 954-954. 2013
- Antithrombotic treatment of splanchnic vein thrombosis in the ISTH international registry: results of 6-month follow-up. Journal of Thrombosis and Haemostasis. 87-88. 2013
- Asian patients with splanchnic vein thrombosis: a sub-analysis from an international registry. Journal of Thrombosis and Haemostasis. 950-951. 2013
- High incidence of VTE despite electronic alerts for thromboprophylaxis in hospitalized cancer patients. Journal of Thrombosis and Haemostasis. 381-381. 2013
- Outcome of patients treated with plasma or prothrombin complex concentrates for warfarin related intracerebral hemorrhage. Journal of Thrombosis and Haemostasis. 555-555. 2013
- Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis. 225-226. 2013
- SUGAMMADEX REVERSAL OF ROCURONIUM- OR VECURONIUM-INDUCED NEUROMUSCULAR BLOCKADE IS NOT ASSOCIATED WITH AN INCREASED RISK OF EITHER BLEEDING OR BLOOD LOSS COMPARED WITH USUAL CARE. Anesthesia and Analgesia. 38-38. 2013
- New anticoagulants in atrial fibrillation management. Thrombosis Research. S63-S66. 2013
- A Multicenter Randomized Placebo Controlled Trial of Compression Stockings to Prevent the Post-Thrombotic Syndrome After Proximal Deep Venous Thrombosis: The S.O.X. Trial. Blood. 393-393. 2012
- A Multicenter Randomized Placebo Controlled Trial of Compression Stockings to Prevent the Post-Thrombotic Syndrome After Proximal Deep Venous Thrombosis: The SOX Trial. Blood. 2012
- Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry. Blood. 2012
- Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry. Blood. 499-499. 2012
- Benefit of Extended Maintenance Therapy for Venous Thromboembolism with Dabigatran Etexilate Is Maintained Over 1 Year of Post-Treatment Follow-up. Blood. 21-21. 2012
- Elevated Risk of Venous but Not Arterial Thrombosis in Waldenström's Macroglobulinemia and Lymphoplasmacytic Lymphoma. Blood. 1603-1603. 2012
- Management and Outcomes of Major Bleeding On Dabigatran or Warfarin. Blood. 19-19. 2012
- Positive Predictive Value of Progressively Elevated D-Dimer Levels in Patients with a Suspected First Deep Vein Thrombosis.. Blood. 2258-2258. 2012
- C0307 Baseline characteristics and management of patients with splanchnic vein thrombosis: Results of an international registry. Thrombosis Research. S188-S189. 2012
- C0322 Factors associated with therapeutic strategies in patients with splanchnic vein thrombosis: Results of an international registry. Thrombosis Research. S125-S126. 2012
- A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II). Blood. 205-205. 2011
- PCV110 Health-Related Quality of Life After Venous Thromboembolism. Value in Health. A384-A384. 2011
- Crystal structure and function of VKOR and its redox partner. Journal of Thrombosis and Haemostasis. 713-713. 2011
- Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis. 731-732. 2011
- Dabigatran vs. placebo for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis. 22-22. 2011
- Fondaparinux treatment of acute heparin-induced thrombocytopenia (HIT) confirmed by a positive serotonin-release assay (SRA plus ). Journal of Thrombosis and Haemostasis. 267-267. 2011
- Four weeks vs. 12 weeks dosing interval for stable patients on warfarin: a randomized trial. Journal of Thrombosis and Haemostasis. 446-446. 2011
- International registry on splanchnic vein thrombosis: description of the study population. Journal of Thrombosis and Haemostasis. 304-304. 2011
- Randomized comparison of the DAWN AC computer program and a simple manual nomogram for quality of warfarin dosing. Journal of Thrombosis and Haemostasis. 302-302. 2011
- Safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy. Journal of Thrombosis and Haemostasis. 479-479. 2011
- Patterns of Management and Adherence to Venous Thromboembolism (VTE) Treatment Guidelines In a National Prospective Cohort Study of VTE Management In the Canadian Outpatient Setting: Recovery Study. Blood. 250-250. 2010
- Arterial and Venous Thrombosis in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Population-Based Study. Blood. 743-743. 2009
- Dabigatran Etexilate Versus Warfarin in the Treatment of Venous Thromboembolism. Blood. 3-3. 2009
- Impact of the Modified Henry Ford Warfarin Maintenance Dosing Algorithm an Quality of Anticoagulation at a Specialist Anticoagulation Clinic. Circulation. S1150-S1150. 2009
- PERIOPERATIVE MANAGEMENT OF ANTICOAGULATION WITH TAPERED DOSE WARFARIN. Haematologica. 147-148. 2008
- Granulocyte-colony stimulating factor - impact on haemostasis in allogeneic stem cell donors. A prospective study. Bone Marrow Transplantation. S193-S193. 2008
- Development of an improved strategy for perioperative bridging of anticoagulation: Predictors of wound hematoma following surgery for permanent pacemakers and implantable defibrillators. Canadian Journal of Cardiology. 174C-174C. 2007
- Safety, tolerability and pharmacokinetics of escalating doses of NXY-059 in healthy young and elderly subjects. Current Medical Research and Opinion. 1813-1823. 2006
- Thromboprophylaxis in Medical Patients – Why Not For All?. Pathophysiology of Haemostasis and Thrombosis: international journal on haemostasis and thrombosis research. 141-145. 2006
- Use of low dose oral vitamin K in the treatment of patients with INR values of more than 10.0.. Blood. 163A-163A. 2005
- Incidence of Recurrent Venous Thromboembolism According to Duration of Vitamin K Antagonists: Results of a Meta-Analysis on Individual Data.. Blood. 710-710. 2004
- Mutation Analysis in F9 Gene of 17 Families with Haemophilia B from Iran. Haemophilia. 751-755. 2004
- Costs and benefits of on-demand and prophylactic treatment strategies for severe haemophilia. A health-economic evaluation.. Blood. 252A-252A. 2003
- Factors at baseline influencing the risk of recurrence in venous thromboembolism: Results of a meta-analysis on individual patient data.. Blood. 209A-209A. 2003
- Influence of age on the risk of recurrence in venous thromboembolism and on the risk of major hemorrhage during oral anticoagulant therapy: Results of a meta-analysis on individual patient data.. Blood. 56A-56A. 2003
- Extended secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. Atherosclerosis. S7-S8. 2003
- Ximelagatran in extended secondary prevention of venous thrombo-embolism-pharmacokinetics and clinical outcome. Atherosclerosis. S6-S6. 2003
- Continuous infusion. Haemophilia. 368-375. 2003
- Unresolved issues in anticoagulant therapy. Journal of Thrombosis and Haemostasis. 1464-1470. 2003
- Experiences of continuous infusion of B-domain deleted recombinant factor VIII (ReFacto (R)) for major surgery.. Blood. 111B-111B. 2002
- Extended secondary prevention with the oral direct thrombin inhibitor ximelagatran for 18 months after 6 months of anticoagulation in patients with venous thromboembolism:: A randomized, placebo-controlled trial.. Blood. 81A-81A. 2002
- Inherited factor VII deficiency and thrombosis in relation to FVII genotype and thrombophilia.. Blood. 267A-267A. 2002
- Efficacy and tolerability of the oral direct thrombin inhibitor Ximelagatran for the treatment of venous thromboembolism.. Journal of General Internal Medicine. 131-131. 2002
- Pharmacokinetics of melagatran after oral dosing with ximelagatran, a direct thrombin inhibitor, in patients with acute venous thromboembolism (VTE).. Clinical Pharmacology and Therapeutics. P61-P61. 2002
- THRIVE I: Efficacy and tolerability of the novel, oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis.. Blood. 447A-448A. 2001
- Recombinant activated factor VII in children with liver disease and coagulopathy. A preliminary study.. Hepatology. 531A-531A. 2001
- Surgery in hemophilia B patients with a chemically treated and virus filtered FIX-concentrate (Nanotiv) in continuous infusion. Thrombosis and Haemostasis. 332-332. 1999
- The risk of ipsilateral versus contralateral recurrent deep vein thrombosis in the leg. Thrombosis and Haemostasis. 259-259. 1999
- For How Long Should the Treatment with Vitamin K Antagonists Be Maintained?. Pathophysiology of Haemostasis and Thrombosis: international journal on haemostasis and thrombosis research. 89-90. 1999
- Optimization of treatment for venous thromboembolism and prevention of recurrences - Co-chairman's summary. Pathophysiology of Haemostasis and Thrombosis: international journal on haemostasis and thrombosis research. 79-80. 1999
- Safety, efficacy and lessons from continuous infusion with rFVIIa. Haemophilia. 564-567. 1998
- Experiences with continuous infusion of recombinant activated factor VII.. Blood Coagulation and Fibrinolysis. S97-101. 1998
- Long-Term Prophylaxis in Venous Thromboembolism: LMWH or Oral Anticoagulation?. Pathophysiology of Haemostasis and Thrombosis: international journal on haemostasis and thrombosis research. 17-21. 1998
- A comparison of six months with indefinite duration of oral anticoagulant therapy after a second episode of venous thromboembolism. Thrombosis and Haemostasis. O2379-O2379. 1997
- Hepatitis C-infected hemophiliacs with a negative PCR reaction for hepatitis C RNA. Thrombosis and Haemostasis. O2467-O2467. 1997
- Preliminary evaluation of factor VIII/vWF concentrate (FANHDI(R)) for continuous infusion: Stability and bacteriological safety. Thrombosis and Haemostasis. PS228-PS228. 1997
- The predictive value of anticardiolipin antibodies in patients with venous thromboembolism.. Thrombosis and Haemostasis. P1470-P1470. 1997
- Design and assessment of clinical trials on continuous infusion.. Blood Coagulation and Fibrinolysis. S7-S9. 1996
- Review of pumps for continuous infusion of coagulation factor concentrates: what are the options?. Blood Coagulation and Fibrinolysis. S27-S33. 1996
- Feasibility of using recombinant factor VIIa in continuous infusion.. Blood. 753-753. 1995
- Home therapy for minor surgery and major bleeding using continuous infusion of monoclonal antibody purified factor VIII concentrate.. Blood. 1395-1395. 1995
- HEPATITIS-E VIRUS-INFECTION IN HEMOPHILIACS. Thrombosis and Haemostasis. 1034-1034. 1995
- INFLUENCE OF CHANGES IN LIFE-STYLE ON FIBRINOLYTIC PARAMETERS AND RECURRENCY RATE IN PATIENTS WITH VENOUS THROMBOEMBOLISM. Thrombosis and Haemostasis. 1147-1147. 1995
- RESISTANCE OF FIBRIN SEALANTS TO PROTEOLYSIS IN A GUINEA-PIG EYE MODEL. Thrombosis and Haemostasis. 1466-1466. 1995
- THE DURATION OF ORAL ANTICOAGULATION AFTER THE 1ST EVENT OF VENOUS THROMBOEMBOLISM - THE DURAC-I TRIAL. Thrombosis and Haemostasis. 1093-1093. 1995
- THE SIGNIFICANCE OF HYPOFIBRINOLYSIS FOR THE RISK OF RECURRENCE OF VENOUS THROMBOEMBOLISM. Thrombosis and Haemostasis. 1097-1097. 1995
- Continuous Infusion of Factor Concentrates: Review of Use in Hemophilia A and Demonstration of Safety and Efficacy in Hemophilia B. Acta Haematologica. 35-42. 1995
- Fibrin Sealant in Surgery of Patients with a Hemorrhagic Diathesis. Thrombosis and Haemostasis. 486-492. 1995
- ADJUSTED-DOSE CONTINUOUS-INFUSION OF FACTOR CONCENTRATE. Blood. A397-A397. 1993
- LOW JUGULAR VENOUS OXYGEN SATURATIONS PRIOR TO DEEP HYPOTHERMIC CIRCULATORY ARREST CORRELATE WITH INCREASED CEREBRAL CELLULAR-METABOLISM. Anesthesiology. A1145-A1145. 1993
- 2 CASES OF BERNARD-SOULIER SYNDROME INVESTIGATED BY FLOW-CYTOMETRY. Thrombosis and Haemostasis. 1143-1143. 1993
- THE EFFECTIVENESS OF DESMOPRESSIN IN PATIENTS WITH DISORDERS OF PRIMARY HEMOSTASIS. DESMOPRESSIN IN BLEEDING DISORDERS. 161-167. 1993
- ANTITHROMBIN-III-STOCKHOLM - A POINT MUTATION IN CODON 392 (GLYCINE TO ASPARTIC-ACID) CAUSING IMPAIRED SERINE PROTEASE REACTIVITY. Thrombosis and Haemostasis. 913-913. 1991
- CLINICAL-EXPERIENCES OF A F-XI-CONCENTRATE - POSSIBLE SIDE-EFFECTS. Thrombosis and Haemostasis. 1157-1157. 1991
- CONTINUOUS REPLACEMENT THERAPY AFTER OPERATIONS IN HEMOPHILIC PATIENTS. Thrombosis and Haemostasis. 1156-1156. 1991
- THE IMPACT OF MONOCLONAL AB PURIFIED PLASMA DERIVED FVIII ON IMMUNE STATUS IN HEMOPHILIA-A PATIENTS. Transfusion. 378-378. 1991
- ANTIHEMOPHILIC-FACTOR ISOLATED WITH MONOCLONAL-ANTIBODIES. HEMOPHILIA AND VON WILLEBRANDS DISEASE IN THE 1990S. 225-230. 1991
- CLINICAL-TRIALS OF RECOMBINANT FACTOR-VIII. RECOMBINANT TECHNOLOGY IN HEMOSTASIS AND THROMBOSIS. 235-241. 1991
- CLINICAL EFFECT OF DDAVP DURING SURGERY OR OTHER PROCEDURES IN PATIENTS WITH HEMOSTATIC DISORDERS. Thrombosis and Haemostasis. 160-160. 1989
- DIAGNOSIS OF PROTEIN-C (PC) DEFICIENCY IN PATIENTS ON ORAL ANTICOAGULATION (OA). Thrombosis and Haemostasis. 274-274. 1989
- HYPERCOAGULABLE STATE FOLLOWING WARFARIN WITHDRAWAL IN PATIENTS GIVEN SECONDARY PROPHYLAXIS WITH ORAL ANTICOAGULATION AFTER MYOCARDIAL-INFARCTION. Thrombosis and Haemostasis. 327-327. 1989
- IMMUNOLOGICAL FUNCTION IN HEMOPHILIACS TREATED WITH PLASMA DERIVED META-AB PURIFIED FVIII CONCENTRATE. Thrombosis and Haemostasis. 181-181. 1989
- INDUCED ANTIBODIES TO VONWILLEBRAND-FACTOR (VWF). Thrombosis and Haemostasis. 361-361. 1987
- INTERACTION BETWEEN IBUPROFEN AND WARFARIN WITH INFLUENCE ON PRIMARY HEMOSTASIS. Scandinavian Journal of Rheumatology. 456-456. 1987
- HTLV-III ANTIBODIES AND LYMPHOCYTE-T SUBSETS IN RELATION TO THERAPY AND CLINICAL DEVELOPMENT IN HEMOPHILIACS. Scandinavian Journal of Immunology. 459-459. 1986
- POSITIVE EFFECT ON HEMOSTASIS BY 1-DEAMINO-8-D-ARGININE VASOPRESSIN (DDAVP) IN CONGENITAL PLATELET-FUNCTION DEFECTS. Thrombosis Research. 27-27. 1986
- LONG-TERM SEQUELAE OF CALF VEIN-THROMBOSIS (CVT) TREATED WITH HEPARIN OR LOW-DOSE STREPTOKINASE. Thrombosis and Haemostasis. 98-98. 1985
- RELATIONSHIP BETWEEN THROMBOEMBOLIC COMPLICATIONS AND INTENSITY OF TREATMENT DURING LONG-TERM PROPHYLAXIS WITH ORAL ANTICOAGULANTS FOLLOWING DEEP-VEIN THROMBOSIS (DVT). Thrombosis and Haemostasis. 101-101. 1985
- THE DURATION OF ORAL ANTICOAGULATION (OA) AFTER DEEP-VEIN THROMBOSIS (DVT) - A RANDOMIZED STUDY. Thrombosis and Haemostasis. 99-99. 1985
- THROMBOLYSIS AND FIBRINOLYTIC PARAMETERS DURING HEPARIN TREATMENT OF DEEP-VEIN THROMBOSIS (DVT). Thrombosis and Haemostasis. 175-175. 1985
- PLASMINOGEN ACTIVATION IN NORMAL INDIVIDUALS AND PATIENTS WITH THROMBOTIC TENDENCY. Thrombosis and Haemostasis. 114-114. 1981
-
journal articles
- Outcomes in children with provoked venous thrombosis and antiphospholipid antibodies: findings from the Kids-DOTT trial.. Blood Advances. 8:5790-5795. 2024
- The Basic Principles of Pathophysiology of Venous Thrombosis.. International Journal of Molecular Sciences. 25:11447. 2024
- Time Trends and Excess Mortality Compared to Population Controls after a First-Time Pulmonary Embolism or Deep Vein Thrombosis.. Thrombosis and Haemostasis. 2024
- "2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19": reply.. Journal of Thrombosis and Haemostasis. 22:2672-2673. 2024
- Recent Advances in Thrombosis and Hemostasis—Part X. Seminars in Thrombosis and Hemostasis. 50:807-808. 2024
- Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper. Thrombosis and Haemostasis. 124:770-777. 2024
- Outcomes of Patients with a Mechanical Heart Valve and Poor Anticoagulation Control on Warfarin. Thrombosis and Haemostasis. 124:613-624. 2024
- Prothrombin complex concentrate for emergency surgery in patients on oral Xa-inhibitors. Journal of Thrombosis and Haemostasis. 22:2761-2766. 2024
- 2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19. Journal of Thrombosis and Haemostasis. 22:1779-1797. 2024
- Coordination of oral anticoagulant care at hospital discharge (COACHeD): pilot randomised controlled trial. BMJ Open. 14:e079353-e079353. 2024
- Periprocedural management of direct oral anticoagulants in patients with atrial fibrillation and active cancer. Journal of Thrombosis and Haemostasis. 22:727-737. 2024
- CHC and surgery: when is stopping safe?. Blood. 143:9-10. 2024
- Antithrombotic management of patients with deep vein thrombosis and venous stents: an international registry. Journal of Thrombosis and Haemostasis. 21:3581-3588. 2023
- Association of type of oral anticoagulation with risk of bleeding in 45,114 patients with venous thromboembolism during initial and extended treatment—A nationwide register‐based study. Journal of Internal Medicine. 294:743-760. 2023
- Anticoagulant Management and Outcomes in Nontraumatic Intracranial Hemorrhage Complicated by Venous Thromboembolism: A Retrospective Chart Review. Thrombosis and Haemostasis. 123:966-975. 2023
- Recent Advances in Thrombosis and Hemostasis—Part IX. Seminars in Thrombosis and Hemostasis. 49:670-672. 2023
- TILE pilot trial study protocol: Tinzaparin Lead-in to Prevent the Post-Thrombotic syndrome study protocol. BMJ Open. 13:e064715-e064715. 2023
- Management of patients on antithrombotic therapy with severe infections: a joint clinical consensus statement of the ESC Working Group on Thrombosis, the ESC Working Group on Atherosclerosis and Vascular Biology, and the International Society on Thrombosis and Haemostasis. European Heart Journal. 44:3040-3058. 2023
- Effect of perioperative benzodiazepine use on intraoperative awareness and postoperative delirium: a systematic review and meta-analysis of randomised controlled trials and observational studies. British Journal of Anaesthesia. 131:302-313. 2023
- Potential for a Virtual Care Model in the Perioperative Management of Anticoagulant Therapy: A 5-Year Retrospective Clinic Review. TH Open. 07:e184-e190. 2023
- Clinical course and treatment of incidentally detected splanchnic vein thrombosis: an individual patient data meta-analysis. Journal of Thrombosis and Haemostasis. 21:1592-1600. 2023
- Antithrombotic therapy in the management of hospitalised patients with COVID-19. British journal of hospital medicine (London, England : 2005). 84:1-11. 2023
- Periprocedural Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant Undergoing a Digestive Endoscopy. American Journal of Gastroenterology. 118:812-819. 2023
- Direct oral anticoagulants versus vitamin K antagonists in the first 3 months after bioprosthetic valve replacement: a systematic review and meta-analysis. European Journal of Cardio-thoracic Surgery. 63:ezad110. 2023
- The risk of major bleeding in patients with factor V Leiden or prothrombin G20210A gene mutation while on extended anticoagulant treatment for venous thromboembolism. Journal of Thrombosis and Haemostasis. 21:553-558. 2023
- Arterial Thrombotic Events in Hospitalized COVID-19 Patients: A Short Review and Meta-Analysis. Seminars in Thrombosis and Hemostasis. 49:047-054. 2023
- How Did We Get Here? Antithrombotic Therapy after Bioprosthetic Aortic Valve Replacement: A Review. Thrombosis and Haemostasis. 123:006-015. 2023
- Coagulation assays and direct oral anticoagulant levels among patients having an elective surgery or procedure. Journal of Thrombosis and Haemostasis. 20:2953-2963. 2022
- Coordination of Oral Anticoagulant Care at Hospital Discharge (COACHeD): protocol for a pilot randomised controlled trial. Pilot and Feasibility Studies. 8:166. 2022
- Frailty phenotype as a predictor of bleeding and mortality in ambulatory patients receiving direct oral anticoagulants. Journal of The American Geriatrics Society. 70:3503-3512. 2022
- “ISTH guidelines for antithrombotic treatment in COVID‐19”: Reply. Journal of Thrombosis and Haemostasis. 20:2710-2711. 2022
- Practical Recommendations for Optimal Thromboprophylaxis in Patients with COVID-19: A Consensus Statement Based on Available Clinical Trials. Journal of Clinical Medicine. 11:5997-5997. 2022
- Good practice statements for antithrombotic therapy in the management of COVID‐19: Guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 20:2226-2236. 2022
- ISTH guidelines for antithrombotic treatment in COVID‐19. Journal of Thrombosis and Haemostasis. 20:2214-2225. 2022
-
Recurrence after stopping anticoagulants in women with combined oral contraceptive‐associated venous thromboembolism: A systematic review and
meta‐analysis . British Journal of Haematology. 199:130-142. 2022 - Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis. Blood Advances. 6:4516-4523. 2022
- Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism. Blood Advances. 6:4605-4616. 2022
- Adherence to apixaban for extended thromboprophylaxis after major abdominal or pelvic surgery for cancer: A prospective cohort study. Journal of Surgical Oncology. 126:386-393. 2022
- Prevention of the Postthrombotic Syndrome with Anticoagulation: A Narrative Review. Thrombosis and Haemostasis. 122:1255-1264. 2022
- 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. Stroke. 53:e282-e361. 2022
- Long-Term Risk of Major Bleeding after Discontinuing Anticoagulation for Unprovoked Venous Thromboembolism: A Systematic Review and Meta-analysis. Thrombosis and Haemostasis. 122:1186-1197. 2022
- Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations–State-of-the-Art. Anticancer Research. 42:3261-3274. 2022
- Profile of Patients with Isolated Distal Deep Vein Thrombosis versus Proximal Deep Vein Thrombosis or Pulmonary Embolism: RE-COVERY DVT/PE Study. Seminars in Thrombosis and Hemostasis. 48:446-458. 2022
- High Factor VIII Levels and Recurrent Thromboembolism in Patients with and without Inflammatory Bowel Disease: A Retrospective Comparative Study. TH Open. 06:e147-e153. 2022
- Diagnosis of deep vein thrombosis with D-dimer adjusted to clinical probability: prospective diagnostic management study. The BMJ. 376:e067378-e067378. 2022
- Carbamazepine, phenytoin, and oral anticoagulants: Drug‐drug interaction and clinical events in a retrospective cohort. Research and Practice in Thrombosis and Haemostasis. 6:e12650-e12650. 2022
- Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism. Journal of the American Medical Association (JAMA). 327:129-129. 2022
- Antithrombotic therapy in COVID-19 patients. Obstetrics, Gynecology and Reproduction. 16:718-731. 2022
- Pathogenetic and prognostic significance of inflammation and altered ADAMTS-13/vWF axis in patients with severe COVID-19. Obstetrics, Gynecology and Reproduction. 16:228-243. 2022
- Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation. ACP journal club. 175:29-35. 2022
- Post‐thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long‐term cross‐sectional follow‐up of RE‐COVER study patients. Journal of Thrombosis and Haemostasis. 19:2495-2503. 2021
- Recurrent bleeding and thrombotic events after resumption of oral anticoagulants following gastrointestinal bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation. Journal of Thrombosis and Haemostasis. 19:2618-2628. 2021
- Arterial Thrombosis in Patients with Antiphospholipid Syndrome: A Review and Meta-Analysis. Seminars in Thrombosis and Hemostasis. 47:709-723. 2021
- Erratum: Arterial Thrombosis in Patients with Antiphospholipid Syndrome: A Review and Meta-Analysis. Seminars in Thrombosis and Hemostasis. 47:e1-e2. 2021
- MUFFIN-PTS trial, Micronized Purified Flavonoid Fraction for the Treatment of Post-Thrombotic Syndrome: protocol of a randomised controlled trial. BMJ Open. 11:e049557-e049557. 2021
- Recent Advances in Thrombosis and Hemostasis—Part VII. Seminars in Thrombosis and Hemostasis. 47:621-622. 2021
- Anticoagulant Treatment of COVID-19 as Early as Possible—Sulodexide and Perspectives. Thrombosis and Haemostasis. 121:849-853. 2021
- Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial. The BMJ. 373:n1205-n1205. 2021
- Clinical history of cancer‐associated splanchnic vein thrombosis. Journal of Thrombosis and Haemostasis. 19:983-991. 2021
- Definition of haemostatic effectiveness in interventions used to treat major bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation. Journal of Thrombosis and Haemostasis. 19:1112-1115. 2021
- Profile of patients diagnosed with acute venous thromboembolism in routine practice according to age and renal function: RE-COVERY DVT/PE study. Journal of Thrombosis and Thrombolysis. 51:561-570. 2021
- New-Onset Atrial Fibrillation in Sepsis: A Narrative Review. Seminars in Thrombosis and Hemostasis. 47:018-025. 2021
- A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome. Pilot and Feasibility Studies. 6:52. 2020
- Correction to: A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome. Pilot and Feasibility Studies. 6:67. 2020
- Venous Thromboembolism in COVID-19. Thrombosis and Haemostasis. 120:1642-1653. 2020
- Rivaroxaban Compared to Placebo for the Treatment of Leg Superficial Vein Thrombosis: A Randomized Trial. Seminars in Thrombosis and Hemostasis. 46:977-985. 2020
- Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study. Journal of the American Heart Association. 9:e017316. 2020
- American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism. Blood Advances. 4:4693-4738. 2020
- Coronavirus Disease 2019, Prothrombotic Factors, and Venous Thromboembolism. Seminars in Thrombosis and Hemostasis. 46:772-776. 2020
- Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure. Blood Advances. 4:3520-3527. 2020
- Is venous thromboembolism a preventable cause of death?. The Lancet Haematology. 7:e555-e556. 2020
- Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE™ Study. American Journal of Medicine. 133:936-945. 2020
- Venous Thromboembolic Diseases: Diagnosis, Management and Thrombophilia Testing: Observations on NICE Guideline [NG158]. Thrombosis and Haemostasis. 120:1143-1146. 2020
- Anticoagulant therapy for splanchnic vein thrombosis. Journal of Thrombosis and Haemostasis. 18:1562-1568. 2020
- Impact of concomitant antiplatelet therapy on the efficacy and safety of direct oral anticoagulants for acute venous thromboembolism: Systematic review and meta‐analysis. Journal of Thrombosis and Haemostasis. 18:1661-1671. 2020
- Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thrombosis and Haemostasis. 120:1004-1024. 2020
- Prophylaxis of Venous Thromboembolism in Patients with Infectious Disease. Tuberculosis and Respiratory Diseases. 83:255-256. 2020
- COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. Journal of the American College of Cardiology. 75:2950-2973. 2020
- Definition of pulmonary embolism‐related death and classification of the cause of death in venous thromboembolism studies: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 18:1495-1500. 2020
- Development of a standardized definition of pulmonary embolism‐related death: A cross‐sectional survey of international thrombosis experts. Journal of Thrombosis and Haemostasis. 18:1415-1420. 2020
- Thrombolytics for venous thromboembolic events: a systematic review with meta-analysis. Blood Advances. 4:1539-1553. 2020
- Home vs hospital treatment of low-risk venous thromboembolism: a systematic review and meta-analysis. Blood Advances. 4:500-513. 2020
- COVID-19, hemostasis disorders and risk of thrombotic complications. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk. 75:306-317. 2020
- Pregnancy-related pelvic vein thrombosis. Obstetrics, Gynecology and Reproduction. 15:627-632. 2020
-
Diagnosis of Pulmonary Embolism with
d -Dimer Adjusted to Clinical Probability. New England Journal of Medicine. 381:2125-2134. 2019 - Four-factor Prothrombin Complex Concentrate for the Management of Patients Receiving Direct Oral Activated Factor X Inhibitors. Anesthesiology. 131:1153-1165. 2019
- Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. JAMA Internal Medicine. 179:1469-1469. 2019
- Healthcare resource utilization and costs among patients with direct oral anticoagulant or warfarin-related major bleeding. Thrombosis Research. 182:12-19. 2019
- Needs and challenges among physicians and researchers in thrombosis and hemostasis: Results from an international study. Research and Practice in Thrombosis and Haemostasis. 3:626-638. 2019
- Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. The BMJ. 366:l4363-l4363. 2019
- Long‐term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d‐dimer results; A cohort study. Journal of Thrombosis and Haemostasis. 17:1144-1152. 2019
- Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation. JAMA cardiology. 4:526-526. 2019
- Thromboprophylaxis in Patients with Acute Spinal Cord Injury: A Narrative Review. Seminars in Thrombosis and Hemostasis. 45:150-156. 2019
- Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. Thrombosis and Haemostasis. 119:319-327. 2019
- Treatment of bleeding complications in patients on anticoagulant therapy. Blood. 133:425-435. 2019
- Management of direct factor Xa inhibitor–related major bleeding with prothrombin complex concentrate: a meta-analysis. Blood Advances. 3:158-167. 2019
- Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review. European Respiratory Review. 27:180094-180094. 2018
- Erratum to: Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study. Thrombosis and Haemostasis. 118:2188-2188. 2018
- Basic coagulation tests as surrogates of dabigatran levels in a pre-operative setting: Analysis of five activated partial thromboplastin time reagents and thrombin time. Thrombosis Research. 171:62-67. 2018
- Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study. Research and Practice in Thrombosis and Haemostasis. 2:684-688. 2018
- Splanchnic vein thrombosis: what are the long-term risks?. The Lancet Haematology. 5:e431-e432. 2018
- Long-Term Outcome of Splanchnic Vein Thrombosis in Cirrhosis. Clinical and Translational Gastroenterology. 9:e176-e176. 2018
- Are NSAIDs Double Trouble?. Journal of the American College of Cardiology. 72:268-270. 2018
- Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. Blood. 131:2151-2160. 2018
- Incidence and risk factors for acute kidney injury in patients with excessive anticoagulation on warfarin: a retrospective study. Journal of Thrombosis and Thrombolysis. 45:557-561. 2018
- Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study. Thrombosis and Haemostasis. 118:842-851. 2018
- Prothrombin complex concentrate for reversal of direct factor Xa inhibitors prior to emergency surgery or invasive procedure: a retrospective study. Journal of Thrombosis and Thrombolysis. 45:486-495. 2018
- Tie2 protects the vasculature against thrombus formation in systemic inflammation. Journal of Clinical Investigation. 128:1471-1484. 2018
- Management of recurrent venous thromboembolism in patients with cancer: A review. Thrombosis Research. 164:S172-S177. 2018
- Perioperative interruption of direct oral anticoagulants in patients with atrial fibrillation: A systematic review and meta‐analysis. Research and Practice in Thrombosis and Haemostasis. 2:282-290. 2018
- Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention. Circulation. 137:307-309. 2018
- Duration of anticoagulant therapy in pediatric venous thromboembolism: Current approaches and updates from randomized controlled trials. Expert Review of Hematology. 11:37-44. 2018
- Correction: Oral anticoagulant re-initiation following intracerebral hemorrhage in non-valvular atrial fibrillation: Global survey of the practices of neurologists, neurosurgeons and thrombosis experts. PLoS ONE. 13:e0198031-e0198031. 2018
- Oral anticoagulant dosing, administration, and storage: a cross-sectional survey of Canadian health care providers. Journal of Thrombosis and Thrombolysis. 45:180-185. 2018
- Oral anticoagulant re-initiation following intracerebral hemorrhage in non-valvular atrial fibrillation: Global survey of the practices of neurologists, neurosurgeons and thrombosis experts. PLoS ONE. 13:e0191137-e0191137. 2018
- Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial. American Heart Journal. 195:108-114. 2018
- Optimal timing of starting thromboprophylaxis for patients with acute spinal cord injury: A survey of Canadian spine surgeons. Thrombosis Research. 160:38-40. 2017
- Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis. Thrombosis Research. 160:97-104. 2017
- Berzelius Symposium 93: International Conference on Thrombosis and Embolism. Seminars in Thrombosis and Hemostasis. 43:811-813. 2017
- Bleeding Complications and Management on anticoagulant therapy. Seminars in Thrombosis and Hemostasis. 43:886-892. 2017
- Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II.. Thrombosis and Haemostasis. 117:2045-2052. 2017
- Recent Advances in Thrombosis and Hemostasis—Part II. Seminars in Thrombosis and Hemostasis. 43:809-810. 2017
- Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood. 130:1706-1712. 2017
- Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood. 130:1706-1712. 2017
- Direct Oral Anticoagulants in the Real World. Canadian Journal of Nursing Research. 49:105-107. 2017
- Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis. BMJ Open. 7:016950-016950. 2017
- Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. Neurology. 89:687-696. 2017
- Assessment of clinically relevant bleeding as a surrogate outcome for major bleeding: validation by meta‐analysis of randomized controlled trials. Journal of Thrombosis and Haemostasis. 15:1547-1558. 2017
- Direct Oral Anticoagulant- or Warfarin-Related Major Bleeding. Chest. 152:81-91. 2017
- How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy. Blood. 129:3285-3293. 2017
- Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER®, RE-COVER™ II, and RE-MEDY™. Journal of Thrombosis and Thrombolysis. 43:484-489. 2017
- Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study. Thrombosis Research. 152:44-48. 2017
- Accumulating data on rivaroxaban for venous thromboembolism in clinical practice. Thrombosis and Haemostasis. 117:1840-1840. 2017
- Acute Unilateral Renal Infarction in the Setting of an Inherited Thrombophilia and Atrial Septal Defect. Case Reports in Hematology. 2017:1-3. 2017
- Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II. Thrombosis and Haemostasis. 117:2045-2052. 2017
- NOACs for treatment of venous thromboembolism in clinical practice. Thrombosis and Haemostasis. 117:1317-1325. 2017
- Optimal timing of vitamin K antagonist resumption after upper gastrointestinal bleeding. Thrombosis and Haemostasis. 117:491-499. 2017
- RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. Thrombosis and Haemostasis. 117:415-421. 2017
- The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale. Thrombosis and Haemostasis. 117:2415-2424. 2017
- Venous thromboembolism: Past, present and future. Thrombosis and Haemostasis. 117:1219-1229. 2017
- Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER™ II, and RE-MEDY™. Vascular Medicine. 21:506-514. 2016
- Incidence and risk factors for venous thromboembolism in patients with acute spinal cord injury: A retrospective study. Thrombosis Research. 147:97-101. 2016
- Periprocedural Management of Direct Oral Anticoagulants Should Be Guided by Accurate Laboratory Tests Reply. Regional Anesthesia and Pain Medicine. 41:788-788. 2016
- Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. European Respiratory Journal. 48:1369-1376. 2016
- Recent Advances in Thrombosis and Hemostasis – Part I. Seminars in Thrombosis and Hemostasis. 42:805-807. 2016
- Update on the Treatment of Venous Thromboembolism. Seminars in Thrombosis and Hemostasis. 42:891-898. 2016
- D-dimer levels and recurrence in patients with unprovoked VTE and a negative qualitative D-dimer test after treatment. Thrombosis Research. 146:119-125. 2016
- Management of venous thromboembolism: an update. Thrombosis Journal. 14:23. 2016
- Development and validation of a decision aid for choosing among antithrombotic agents for atrial fibrillation. Thrombosis Research. 145:143-148. 2016
- A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. Blood. 127:2791-2803. 2016
- Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry. The Lancet Haematology. 3:e267-e275. 2016
- Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events. Thrombosis Research. 140:81-88. 2016
- Management of bleeding complications in patients with cancer on DOACs. Thrombosis Research. 140:S142-S147. 2016
- Less menorrhagia for women with VTE. Blood. 127:1378-1379. 2016
- Bleeding events with dabigatran or warfarin in patients with venous thromboembolism. Thrombosis and Haemostasis. 115:291-298. 2016
- Rapid quantitative D‐dimer to exclude pulmonary embolism: a prospective cohort management study. Journal of Thrombosis and Haemostasis. 14:504-509. 2016
- Appropriateness of Apixaban Dosing to Prevent Stroke in Patients with Atrial Fibrillation: A Pilot Study. Canadian Journal of Hospital Pharmacy. 69:449-453. 2016
- Assessment of effectiveness of major bleeding management: proposed definitions for effective hemostasis: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 14:211-214. 2016
- Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation. Thrombosis and Haemostasis. 116:544-553. 2016
- Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure. Journal of Thrombosis and Haemostasis. 14:89-97. 2016
- Matching genes with constitution and environment. Thrombosis and Haemostasis. 116:592-594. 2016
- Periprocedural Management of Direct Oral Anticoagulants. Regional Anesthesia and Pain Medicine. 41:127-129. 2016
- The effect of low-dose oral vitamin K supplementation on INR stability in patients receiving warfarin. Thrombosis and Haemostasis. 116:480-485. 2016
- Treatment of acute pulmonary embolism with dabigatran versus warfarin. Thrombosis and Haemostasis. 116:714-721. 2016
- Selexipag for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine. 373:2522-2533. 2015
- Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 13:2119-2126. 2015
- Strategies and outcomes of periprocedural bridging therapy with low-molecular-weight heparin in patients with mechanical heart valves. Journal of Thrombosis and Thrombolysis. 40:430-436. 2015
- Association between inflammation biomarkers, anatomic extent of deep venous thrombosis, and venous symptoms after deep venous thrombosis. Journal of Vascular Surgery: Venous and Lymphatic Disorders. 3:347-353.e1. 2015
- Long-term Clinical Outcomes of Splanchnic Vein Thrombosis. JAMA Internal Medicine. 175:1474-1474. 2015
- Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids‐DOTT trial): pilot/feasibility phase findings. Journal of Thrombosis and Haemostasis. 13:1597-1605. 2015
- Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. New England Journal of Medicine. 373:823-833. 2015
- Perioperative Management of Dabigatran. Circulation. 132:167-173. 2015
- Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. Journal of Thrombosis and Haemostasis. 13:1010-1018. 2015
- A Double-Blind, Randomized Controlled Trial of the Prevention of Clinically Important Venous Thromboembolism After Isolated Lower Leg Fractures. Journal of Orthopaedic Trauma. 29:224-230. 2015
- Anticoagulation for stroke prevention in new atrial fibrillation after coronary artery bypass graft surgery. Thrombosis Research. 135:841-845. 2015
- Management of new oral anticoagulants related life threatening or major bleedings in real life: a brief report. Journal of Thrombosis and Thrombolysis. 39:427-433. 2015
- Clinical Experience With the New Oral Anticoagulants for Treatment of Venous Thromboembolism. Arteriosclerosis, Thrombosis and Vascular Biology. 35:513-519. 2015
- Inflammation markers and their trajectories after deep vein thrombosis in relation to risk of post‐thrombotic syndrome. Journal of Thrombosis and Haemostasis. 13:398-408. 2015
- Real‐world variability in dabigatran levels in patients with atrial fibrillation. Journal of Thrombosis and Haemostasis. 13:353-359. 2015
- Treatment of Venous Thromboembolism with New Oral Anticoagulants According to Patient Risk. Seminars in Thrombosis and Hemostasis. 41:160-165. 2015
- Association of Venous Thromboembolism With Hormonal Contraception and Thrombophilic Genotypes (vol 124, pg 600, 2014). Obstetrics and Gynecology. 125:495-495. 2015
- Thrombin generation test in children and adolescents with chronic liver disease. Thrombosis Research. 135:382-387. 2015
-
d -Dimer Testing to Select Patients With a First Unprovoked Venous Thromboembolism Who Can Stop Anticoagulant Therapy. ACP journal club. 162:27-34. 2015 - Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thrombosis and Haemostasis. 114:150-157. 2015
- Effect of Reversal of Neuromuscular Blockade with Sugammadex versus Usual Care on Bleeding Risk in a Randomized Study of Surgical Patients. Anesthesiology. 121:969-977. 2014
- Elevated risk of venous but not arterial thrombosis in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. Journal of Thrombosis and Haemostasis. 12:1816-1821. 2014
- When the Rubber Meets the Road: Adherence and Persistence with Non–Vitamin K Antagonist Oral Anticoagulants and Old Oral Anticoagulants in the Real World—A Problem or A Myth ?. Seminars in Thrombosis and Hemostasis. 40:852-859. 2014
- Reduced-dose warfarin or interrupted warfarin with heparin bridging for pacemaker or defibrillator implantation: A randomized trial. Thrombosis Research. 134:814-818. 2014
- Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 124:1968-1975. 2014
- Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.. Blood. 124:1968-1975. 2014
- Response to Letter Regarding Article, “Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin”. Circulation. 130:e95. 2014
- Association of Venous Thromboembolism With Hormonal Contraception and Thrombophilic Genotypes. Obstetrics and Gynecology. 124:600-609. 2014
- Loading dose vs. maintenance dose of warfarin for reinitiation after invasive procedures: a randomized trial. Journal of Thrombosis and Haemostasis. 12:1254-1259. 2014
- Distal deep vein thrombosis – a benign disease?. Thrombosis Research. 134:5-6. 2014
- Venous Thromboembolism in Older Adults: A Community-based Study. American Journal of Medicine. 127:530-537.e3. 2014
- Cluster randomized controlled trial of a simple warfarin maintenance dosing algorithm versus usual care among primary care practices. Journal of Thrombosis and Thrombolysis. 37:435-442. 2014
- Potential antidotes for reversal of old and new oral anticoagulants. Thrombosis Research. 133:S158-S166. 2014
- Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. The Lancet. 383:880-888. 2014
- Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis. Circulation. 129:764-772. 2014
- Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry. Seminars in Thrombosis and Hemostasis. 40:099-105. 2014
- Activated prothrombin complex concentrate for dabigatran‐associated bleeding. British Journal of Haematology. 164:308-310. 2014
- Advantages and limitations of the new anticoagulants. Journal of Internal Medicine. 275:1-11. 2014
- Graduated compression stockings to treat acute leg pain associated with proximal DVT. Thrombosis and Haemostasis. 112:1137-1141. 2014
- Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate. Thrombosis and Haemostasis. 112:233-239. 2014
- New oral anticoagulant agents – general features and outcomes in subsets of patients. Thrombosis and Haemostasis. 111:575-582. 2014
- Shorter or longer anticoagulation to prevent recurrent venous thromboembolism: systematic review and meta-analysis. BMJ Open. 4:e005674-e005674. 2014
- Systematic Review of Observational Studies Assessing Bleeding Risk in Patients with Atrial Fibrillation Not Using Anticoagulants. PLoS ONE. 9:e88131-e88131. 2014
- Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin. Circulation. 128:2325-2332. 2013
-
Anticoagulation Control with Daily Low‐Dose Vitamin
K to Reduce Clinically Adverse Outcomes and International Normalized Ratio Variability: A Systematic Review and Meta‐Analysis. Pharmacotherapy. 33:1184-1190. 2013 - Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor/factor VIII concentrate in adults and children with von Willebrand's disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials.. Blood Transfusion. 11:533-540. 2013
- Safety and Efficacy of Dabigatran Compared With Warfarin for Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-analysis. Canadian Journal of Cardiology. 29:1203-1210. 2013
- Secondary prevention of venous thromboembolism. The BMJ. 347:f5440-f5440. 2013
- Bleeding Risk in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Systematic Review and Meta-Analysis. Clinical Pharmacology and Therapeutics. 94:367-375. 2013
- Oral Apixaban for the Treatment of Acute Venous Thromboembolism. New England Journal of Medicine. 369:799-808. 2013
- Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach. Journal of Thrombosis and Haemostasis. 11:1443-1448. 2013
- Adherence to anticoagulant treatment with dabigatran in a real‐world setting. Journal of Thrombosis and Haemostasis. 11:1295-1299. 2013
- Extended Anticoagulation in Venous Thromboembolism. New England Journal of Medicine. 368:2328-2329. 2013
- Extended anticoagulation in venous thromboembolism.. New England Journal of Medicine. 368:2329. 2013
- Extended anticoagulation in venous thromboembolism.. New England Journal of Medicine. 368:2329. 2013
- Extended anticoagulation in venous thromboembolism.. New England Journal of Medicine. 368:2328-2329. 2013
- Bleeding and antidotes in new oral anticoagulants. Best Practice and Research in Clinical Haematology. 26:191-202. 2013
- American College of Chest Physicians Guidelines for Heparin-Induced Thrombocytopenia: Response. Chest. 143:1191-1191. 2013
- Anticoagulation management in patients with mechanical heart valves having pacemaker or defibrillator insertion. Thrombosis Research. 131:300-303. 2013
- Optimal Duration of Anticoagulant Therapy. Seminars in Thrombosis and Hemostasis. 39:141-146. 2013
- Supplemental patient education for patients taking oral anticoagulants: systematic review and meta-analysis. Journal of Thrombosis and Haemostasis. 11:491-502. 2013
- The accuracy of the International Normalized Ratio and the American College of Chest Physicians recommendations on the use of vitamin K to reverse over-anticoagulation: a rebuttal. Journal of Thrombosis and Haemostasis. 11:566-567. 2013
- Tossing a coin or using common sense. Journal of Thrombosis and Haemostasis. 11:432-434. 2013
- Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism. New England Journal of Medicine. 368:709-718. 2013
- Bile acids and coagulation factors. European Journal of Gastroenterology and Hepatology. 25:152-158. 2013
-
Selective
d -Dimer Testing for Diagnosis of a First Suspected Episode of Deep Venous Thrombosis. ACP journal club. 158:93-93. 2013 - High incidence of venous thromboembolism despite electronic alerts for thromboprophylaxis in hospitalised cancer patients. Thrombosis and Haemostasis. 110:184-190. 2013
- Respiratory Review of 2013: Pulmonary Thromboembolism. Tuberculosis and Respiratory Diseases. 75:89-89. 2013
- Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation.. Journal of Population Therapeutics and Clinical Pharmacology. 20:e229-e237. 2013
- Comparative effectiveness and safety of the novel oral anticoagulants: do the pivotal clinical trials point to a new paradigm?. Journal of Thrombosis and Haemostasis. 10:2621-2624. 2012
- Should vitamin K antagonist therapy be started simultaneously with parenteral anticoagulation. Blood Coagulation and Fibrinolysis. 23:705-713. 2012
- Thrombosis is associated with inferior survival in multiple myeloma. Haematologica. 97:1603-1607. 2012
- Accuracy and safety of 99mTc-labeled anti-D-dimer (DI-80B3) Fab’ fragments (ThromboView®) in the diagnosis of deep vein thrombosis: A phase II study. Thrombosis Research. 130:381-389. 2012
- Advances in the management of venous thromboembolism. Best Practice and Research in Clinical Haematology. 25:361-377. 2012
- Advances in the management of venous thromboembolism.. Best Practice and Research in Clinical Haematology. 25:361-377. 2012
- Treatment of venous thromboembolism with dabigatran. Current Opinion in Pulmonary Medicine. 18:410-415. 2012
- Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban. Journal of Thrombosis and Haemostasis. 10:1433-1436. 2012
- When is it safe to stop for safety?. Journal of Thrombosis and Haemostasis. 10:1188-1190. 2012
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. New England Journal of Medicine. 366:1287-1297. 2012
- Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy. Journal of Thrombosis and Haemostasis. 10:692-694. 2012
- How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 119:3016-3023. 2012
- Is the warfarin saga over?. The journal of the Royal College of Physicians of Edinburgh. 42:51-55. 2012
- Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurology. 11:225-231. 2012
- Antithrombotic Therapy for Atrial Fibrillation. Chest. 141:e531S-e575S. 2012
- Evidence-Based Management of Anticoagulant Therapy. Chest. 141:e152S-e184S. 2012
- Prevention of VTE in Orthopedic Surgery Patients. Chest. 141:e278S-e325S. 2012
- The Oral Thrombin Inhibitor Dabigatran: Strengths and Weaknesses. Seminars in Thrombosis and Hemostasis. 38:07-15. 2012
- Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy. Thrombosis Research. 129:146-151. 2012
- Treatment and Prevention of Heparin-Induced Thrombocytopenia. Chest. 141:e495S-e530S. 2012
- Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 141:e601S-e636S. 2012
- Is the network meta-analysis (NETMA) bringing us closer to the truth? Insights from recent antithrombotic drug data. Thrombosis and Haemostasis. 108:872-875. 2012
- Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. Thrombosis and Haemostasis. 108:493-498. 2012
- Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 141:53S-70S. 2012
- Pharmacologic tools to reduce bleeding in surgery.. Hematology. American Society of Hematology. Education Program. 2012:517-521. 2012
- Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 141:e195S-e226S. 2012
- Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. Thrombosis and Haemostasis. 108:1228-1235. 2012
- Fondaparinux treatment of acute heparin‐induced thrombocytopenia confirmed by the serotonin‐release assay: a 30‐month, 16‐patient case series. Journal of Thrombosis and Haemostasis. 9:2389-2396. 2011
- Relative importance of patient, procedural and anatomic risk factors for early vein graft thrombosis after coronary artery bypass graft surgery.. Journal of Cardiovascular Surgery. 52:877-885. 2011
- Resumption of Oral Anticoagulation After Warfarin-Associated Intracerebral Hemorrhage. Stroke. 42:3663-3664. 2011
- Warfarin Dose Assessment Every 4 Weeks Versus Every 12 Weeks in Patients With Stable International Normalized Ratios. ACP journal club. 155:653-653. 2011
- A Benefit-Risk Assessment of Dabigatran in the Prevention of Venous Thromboembolism in Orthopaedic Surgery. Drug Safety. 34:449-463. 2011
- Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. The BMJ. 342:d3036-d3036. 2011
- Apixaban in Patients with Atrial Fibrillation. New England Journal of Medicine. 364:806-817. 2011
- Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model. Blood. 117:2089-2092. 2011
- A prospective study of an aggressive warfarin dosing algorithm to reach and maintain INR 2 to 3 after heart valve surgery. Thrombosis and Haemostasis. 105:232-238. 2011
- Hypercoagulability in Multiple Myeloma and Its Precursor State, Monoclonal Gammopathy of Undetermined Significance. Seminars in Hematology. 48:46-54. 2011
- Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement. New England Journal of Medicine. 363:2487-2498. 2010
- Oral Rivaroxaban for Symptomatic Venous Thromboembolism. New England Journal of Medicine. 363:2499-2510. 2010
- Optimal Timing of Resumption of Warfarin After Intracranial Hemorrhage. Stroke. 41:2860-2866. 2010
- Enoxaparin Versus Dabigatran or Rivaroxaban for Thromboprophylaxis After Hip or Knee Arthroplasty. Circulation. Cardiovascular Quality and Outcomes. 3:652-660. 2010
- Direct and indirect costs of management of long‐term warfarin therapy in Canada. Journal of Thrombosis and Haemostasis. 8:2192-2200. 2010
- Fondaparinux for the Treatment of Superficial-Vein Thrombosis in the Legs. New England Journal of Medicine. 363:1222-1232. 2010
- New aspects on treatment modalities for thromboembolic episodes. Journal of Internal Medicine. 268:109-119. 2010
- Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood. 115:4991-4998. 2010
- Definition of major bleeding in surgery: an anesthesiologist’s point of view: reply to a rebuttal. Journal of Thrombosis and Haemostasis. 8:1443-1444. 2010
- Single-dose adjustment versus no adjustment of warfarin in stably anticoagulated patients with an occasional international normalized ratio (INR) out of range. Thrombosis Research. 125:393-397. 2010
- Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding. Journal of Thrombosis and Haemostasis. 8:641-650. 2010
- Dabigatran versus Warfarin for Venous Thromboembolism. New England Journal of Medicine. 362:1050-1051. 2010
- Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. The Lancet. 375:807-815. 2010
- Decreasing warfarin sensitivity during the first three months after heart valve surgery: Implications for dosing. Thrombosis Research. 125:224-229. 2010
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. Journal of Thrombosis and Haemostasis. 8:202-204. 2010
- Effect of a simple two‐step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study. Journal of Thrombosis and Haemostasis. 8:101-106. 2010
- Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10. Thrombosis and Haemostasis. 104:118-121. 2010
- Thrombin generation in vitro in the presence of by‐passing agents in siblings with severe haemophilia A. Haemophilia. 16:e210-e215. 2010
- Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. New England Journal of Medicine. 361:2342-2352. 2009
- Rivaroxaban in Orthopedic Surgery — A Change of Paradigm?. Clinical and Applied Thrombosis/Hemostasis. 15:613-620. 2009
- The absence of `minor' risk factors for recurrent venous thromboembolism: a systematic review of negative predictive values and negative likelihood ratios. Journal of Thrombosis and Haemostasis. 7:1619-1628. 2009
- Dabigatran versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine. 361:1139-1151. 2009
- Effect of anti‐platelet factor‐4/heparin antibody induction on early saphenous vein graft occlusion after coronary artery bypass surgery. Journal of Thrombosis and Haemostasis. 7:1457-1464. 2009
- Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. American Journal of Hematology. 84:579-583. 2009
- Getting intimate with the venous thrombus. Journal of Thrombosis and Haemostasis. 7:1266-1267. 2009
- Recommendations on biosimilar low‐molecular‐weight heparins. Journal of Thrombosis and Haemostasis. 7:1222-1225. 2009
- 6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII. Annals of Hematology. 88:485-490. 2009
- Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. The Lancet. 373:1673-1680. 2009
- Cervical artery dissection: Pathology, epidemiology and management. Thrombosis Research. 123:810-821. 2009
- Oral Vitamin K Versus Placebo to Correct Excessive Anticoagulation in Patients Receiving Warfarin. ACP journal club. 150:293-293. 2009
- Postoperative Low‐Molecular‐Weight Heparin Bridging Is Associated with an Increase in Wound Hematoma Following Surgery for Pacemakers and Implantable Defibrillators. PACE - Pacing and Clinical Electrophysiology. 32:378-382. 2009
- The plasma concentration of activated protein C appears normal in patients with haemophilia. Haemophilia. 15:566-570. 2009
- Dabigatran Etexilate: Future Directions in Anticoagulant Treatment. Clinical and Applied Thrombosis/Hemostasis. 15:32S-41S. 2009
- Factor VII deficiency: clinical manifestation of 717 subjects from Europe and Latin America with mutations in the factor 7 gene. Haemophilia. 15:267-280. 2009
- Treatment and prevention of acute bleedings in von Willebrand disease – efficacy and safety of Wilate®, a new generation von Willebrand factor/factor VIII concentrate. Haemophilia. 15:122-130. 2009
- Low PAI‐1 activity in relation to inflammatory parameters, insulin profile and body mass index. Journal of Internal Medicine. 264:586-592. 2008
- The future management of thromboembolic disorders: Is there a need for new and improved thromboembolic treatment and management strategies?. Thrombosis and Haemostasis. 100:A3-A6. 2008
- Thrombophilic polymorphism – a short‐term or long‐term risk for recurrence?. Journal of Thrombosis and Haemostasis. 6:2225-2226. 2008
- Determinants of Bleeding Risk in Patients on Antithrombotic and Antifibrinolytic Drugs. Seminars in Thrombosis and Hemostasis. 34:762-771. 2008
- Response to: the ethical problem and the risk of haemorrhage. Journal of Internal Medicine. 264:503-503. 2008
- Perioperative anticoagulation in patients having implantation of a cardiac pacemaker or defibrillator: a systematic review and practical management guide. Journal of Thrombosis and Haemostasis. 6:1615-1621. 2008
- More on: vitamin K antagonists and cancer. Journal of Thrombosis and Haemostasis. 6:1442-1443. 2008
- Variability of clinical manifestation of factor VII-deficiency in homozygous and heterozygous subjects of the European F7 gene mutation A294V. Haematologica. 93:1273-1275. 2008
- Validation of a composite score for clinical severity of hemophilia. Journal of Thrombosis and Haemostasis. 6:1113-1121. 2008
- Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment. Chest. 133:257S-298S. 2008
- [Bleeding time--only in special cases. The method is of little value as a general screening analysis].. Lakartidningen. 105:1268. 2008
- Clinical factors influencing the sensitivity to warfarin when restarted after surgery. Journal of Internal Medicine. 263:412-419. 2008
- Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations. Thrombosis and Haemostasis. 99:616-622. 2008
- Clinical factors influencing normalization of prothrombin time after stopping warfarin: a retrospective cohort study. Thrombosis Journal. 6:15-15. 2008
- Current strategies in prophylaxis and treatment of venous thromboembolism. Annals of Medicine. 40:352-359. 2008
- Extension of anticoagulation after venous thromboembolism. Hamostaseologie. 28:110-119. 2008
- The Risk for Fatal Pulmonary Embolism after Discontinuing Anticoagulant Therapy for Venous Thromboembolism. ACP journal club. 147:766-766. 2007
- Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity. Blood Coagulation and Fibrinolysis. 18:657-660. 2007
- Thrombophilia and location of venous thromboembolism. Journal of Thrombosis and Haemostasis. 5:2151-2152. 2007
- Is 3 months the optimum duration of anticoagulation therapy for deep vein thrombosis and pulmonary embolism?. Nature Reviews Cardiology. 4:472-473. 2007
- NXY‐059 Does Not Affect Bleeding Time in Healthy Volunteers: A Randomized, Double‐Blind, Placebo‐Controlled, 3‐Period Crossover Phase I Study. Journal of Clinical Pharmacology. 47:264-272. 2007
- Anticoagulants and Their Reversal. Transfusion Medicine Reviews. 21:37-48. 2007
- Confusion around the official classification of arthropathy. Haemophilia. 13:117-119. 2007
- Low PAI-1 activity in relation to the risk for perioperative bleeding complications in transurethral resection of the prostate. Thrombosis Research. 119:715-721. 2007
- Optimal reversal of vitamin K antagonists. Thrombosis Research. 119:15-16. 2007
- The onerous task of comparing treatments in inhibitor patients. Thrombosis and Haemostasis. 98:710-712. 2007
- Can fondaparinux safely prevent the occurrence of venous thromboembolism in acutely ill medical patients?. Nature Reviews Cardiology. 3:358-359. 2006
- Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. The Lancet. 368:371-378. 2006
- An illustrative case and a review on the dosing of recombinant factor VIIa in congenital factor XI deficiency. Haemophilia. 12:223-227. 2006
- Post‐thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. Journal of Thrombosis and Haemostasis. 4:734-742. 2006
- Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long‐term secondary prevention of venous thromboembolism. British Journal of Haematology. 133:68-77. 2006
- Evaluation of low PAI‐1 activity as a risk factor for hemorrhagic diathesis. Journal of Thrombosis and Haemostasis. 4:201-208. 2006
- New concepts in optimal management of anticoagulant therapy for extended treatment of venous thromboembolism. Thrombosis and Haemostasis. 96:258-266. 2006
- A Step Change in Oral Anticoagulation: Lack of Coagulation Monitoring with Ximelagatran. Seminars in Thrombosis and Hemostasis. 5:259-265. 2005
- Ximelagatran in the Clinic: Practical Management of Patients. Seminars in Thrombosis and Hemostasis. 5:301-307. 2005
- Patient self-management of anticoagulants reduced arterial thromboembolism and adverse effects. ACP journal club. 143:8-8. 2005
- Risk of bleeding with long-term antithrombotic therapy in atrial fibrillation. European Heart Journal, Supplement. 7:C34-C40. 2005
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients. Journal of Thrombosis and Haemostasis. 3:692-694. 2005
- Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. Clinical Pharmacology and Therapeutics. 77:279-290. 2005
- Hypercoagulability preceding cancer. Journal of Thrombosis and Haemostasis. 3:581-583. 2005
- Continuous infusion of recombinant factor VIIa for surgery in patients with deficiency of factor VII. Thrombosis and Haemostasis. 94:1177-1180. 2005
- General Discussion. Pathophysiology of Haemostasis and Thrombosis: international journal on haemostasis and thrombosis research. 34:31-34. 2005
- Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran. Thrombosis and Haemostasis. 94:522-527. 2005
- Recombinant FVIIa in children with liver disease. Thrombosis Research. 116:185-197. 2005
- The Role of Ximelagatran in the Treatment of Venous Thromboembolism. Pathophysiology of Haemostasis and Thrombosis: international journal on haemostasis and thrombosis research. 34:18-24. 2005
- Ximelagatran for the secondary prevention of venous thromboembolism. Thrombosis and Haemostasis. 94:820-824. 2005
- Continuous infusion of B‐domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience. Haemophilia. 10:452-458. 2004
- Costs of on‐demand and prophylactic treatment for severe haemophilia in Norway and Sweden. Haemophilia. 10:515-526. 2004
- Hemorrhagic Complications of Anticoagulant Treatment. Chest. 126:287S-310S. 2004
- [Low molecular weight heparin--a safer anticoagulant in thrombosis and cancer].. Lakartidningen. 101:1712-1715. 2004
- Ximelagatran for Secondary Prevention of Venous Thromboembolism. New England Journal of Medicine. 350:618-619. 2004
- Vitamin K antagonists and cancer: rebuttal. Journal of Thrombosis and Haemostasis. 2:346-379. 2004
- A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis. 2:47-53. 2004
- Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?. Scandinavian Journal of Clinical and Laboratory Investigation. 64:745-752. 2004
- Acquired hemophilia masked by warfarin therapy. Blood Coagulation and Fibrinolysis. 14:769-772. 2003
- Long-term anticoagulant therapy - Reply. New England Journal of Medicine. 349:1976-1977. 2003
- Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran. New England Journal of Medicine. 349:1713-1721. 2003
- Novel anticoagulant agents: introduction. Journal of Internal Medicine. 254:308-312. 2003
- Thrombosis in inherited factor VII deficiency. Journal of Thrombosis and Haemostasis. 1:2153-2158. 2003
- Low-intensity warfarin therapy prevented recurrent venous thromboembolism. ACP journal club. 139:42-42. 2003
- On‐demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia. 9:555-566. 2003
- Care of Patients Receiving Long-Term Anticoagulant Therapy. New England Journal of Medicine. 349:675-683. 2003
- [There is evidence for prolonged low-intensity warfarin therapy after venous thrombosis].. Lakartidningen. 100:2118-2121. 2003
- Acute thrombosis of a separate major coronary artery during initially successful thrombolytic therapy. International Journal of Cardiology. 89:97-99. 2003
- Continuous intravenous infusion of a plasma‐derived factor IX concentrate (Mononine®) in haemophilia B. Haemophilia. 9:164-172. 2003
- Limited Protective Effect of the CCR5Δ32/CCR5Δ32 Genotype on Human Immunodeficiency Virus Infection Incidence in a Cohort of Patients with Hemophilia and Selection for Genotypic X4 Virus. Journal of Infectious Diseases. 187:215-225. 2003
- A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. Journal of Thrombosis and Haemostasis. 1:41-47. 2003
- Helicobacter pylori causes gastrointestinal hemorrhage in patients with congenital bleeding disorders. Thrombosis and Haemostasis. 89:741-746. 2003
- Platelet-leukocyte aggregation under shear stress: Differential involvement of selectins and integrins. Thrombosis and Haemostasis. 90:679-687. 2003
- Why Is Factor Xa Not a Better Target Than Factor IIa for Therapeutic Inhibition of Coagulation?. Seminars in Thrombosis and Hemostasis. 29:033-036. 2003
- Acquired platelet dysfunction may be an aetiologic factor in Heyde's syndrome – normalization of bleeding time after aortic valve replacement. Journal of Internal Medicine. 252:516-523. 2002
- Hypofibrinolytic State in HIV-1–Infected Patients Treated With Protease Inhibitor–Containing Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999). 29:441-449. 2002
- Discrepancy between antithrombin activity methods revealed in Antithrombin Stockholm: do factor Xa–based methods overestimate antithrombin activity in some patients?. Blood. 99:2271-2272. 2002
- A randomized study of alpha‐interferon plus ribavirin for 6 months or 12 months for the treatment of chronic hepatitis C in patients with bleeding disorders. Haemophilia. 8:129-135. 2002
- Experiences of a low-intensity anticoagulation regimen for extended secondary prevention of venous thromboembolism. Haematologica. 3:311-314. 2002
- Inhibition of Warfarin Activity by Ribavirin. Annals of Pharmacotherapy. 36:72-74. 2002
- Pregnancy, Heparin and Osteoporosis. Thrombosis and Haemostasis. 87:180-181. 2002
- [Cure of hemophilia is approaching. Gene therapy is the hope].. Lakartidningen. 98:5454-5457. 2001
- Total thrombin‐activatable fibrinolysis inhibitor (TAFI) antigen and pro‐TAFI in patients with haemophilia A. Haemophilia. 7:557-560. 2001
- Author’s reply. Journal of Internal Medicine. 250:260-261. 2001
- [Prothromplex in stead of Beriplex P/N as acute antidote against warfarin].. Lakartidningen. 98:3807. 2001
- Modification of von Willebrand Disease after Liver Transplantation. Thrombosis and Haemostasis. 86:1588-1589. 2001
- Venous thromboembolism and cancer. Reply. New England Journal of Medicine. 343:1338-1338. 2000
- [Venous thromboembolism, warfarin and cancer--a well-known connection].. Lakartidningen. 97:4554. 2000
- Duration of anticoagulants in acute or recurrent venous thromboembolism. Current Opinion in Pulmonary Medicine. 6:321-325. 2000
- Incidence of Cancer after Prophylaxis with Warfarin against Recurrent Venous Thromboembolism. New England Journal of Medicine. 342:1953-1958. 2000
- Molecular genetic analysis of severe protein C deficiency.. Human Genetics. 106:646-653. 2000
- The risk of ipsilateral versus contralateral recurrent deep vein thrombosis in the leg. Journal of Internal Medicine. 247:601-606. 2000
- The risk of ipsilateral versus contralateral recurrent deep vein thrombosis in the leg. The DURAC Trial Study Group.. Journal of Internal Medicine. 247:601-606. 2000
- [Length of treatment in deep venous thrombosis--some comments].. Lakartidningen. 97:862-864. 2000
- Continuous Infusion of Recombinant Factor VIIa in Hemophilic Patients with Inhibitors: Safety, Monitoring, and Cost Effectiveness. Seminars in Thrombosis and Hemostasis. Volume 26:0421-0424. 2000
- Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. British Journal of Haematology. 105:1109-1113. 1999
- Haemostatic and replacement therapy in von Willebrand disease. Haemophilia. 5:57-59. 1999
- The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation.. Thrombosis and Haemostasis. 81:684-689. 1999
- von Willebrand disease: an update in the Åland islandsSummary of a Nordic Symposium on von Willebrand disease, 24–25 September 1998, Mariehamn, Åland. Haemophilia. 5:1-6. 1999
- [Centralized care is the basis of care programs for hemophilia patients].. Lakartidningen. 96:1849-1852. 1999
- Introduction. Journal of Internal Medicine. 245:367-368. 1999
- Oral anticoagulation in venous thromboembolism: decisions based on more than mere feelings. Journal of Internal Medicine. 245:399-399. 1999
- Oral anticoagulation – how intense and for how long?. Journal of Internal Medicine. 245:365-366. 1999
- Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery. Haemophilia. 5:96-96. 1999
- Characteristics of septic arthritis in human immunodeficiency virus- infected haemophiliacs versus other risk groups. Rheumatology. 38:139-142. 1999
- Optimization of Treatment for Venous Thromboembolism and Prevention of Recurrences. Pathophysiology of Haemostasis and Thrombosis: international journal on haemostasis and thrombosis research. 29:79-80. 1999
- Safety and Efficacy of Continuous Infusion of a Combined Factor VIII – von Willebrand Factor (vWF) Concentrate (Haemate-P™) in Patients with von Willebrand Disease. Thrombosis and Haemostasis. 81:229-233. 1999
- The Risk of Recurrent Venous Thromboembolism in Carriers and Non-carriers of the G1691A Allele in the Coagulation Factor V Gene and the G20210A Allele in the Prothrombin Gene. Thrombosis and Haemostasis. 81:684-689. 1999
- The effect of the duration of anticoagulation and other risk factors on the recurrence of venous thromboembolisms. Duration of Anticoagulation Study Group.. Wiener Medizinische Wochenschrift. 149:66-69. 1999
- Major surgery seems not to influence HIV disease progression in haemophilia patients. British Journal of Haematology. 103:10-14. 1998
- Therapies for ulcers associated with nonsteroidal antiinflammatory drugs.. New England Journal of Medicine. 339:350-351. 1998
- Safety, efficacy and lessons from continuous infusion with rFVIIa. rFVIIa-CI Group.. Haemophilia. 4:564-567. 1998
- Anticardiolipin Antibodies Predict Early Recurrence of Thromboembolism and Death Among Patients with Venous Thromboembolism Following Anticoagulant Therapy. American Journal of Medicine. 104:332-338. 1998
- Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group.. American Journal of Medicine. 104:332-338. 1998
- Hepatitis C Virus-infected, HCV-RNA-negative Patients with Bleeding Disorders - Relationship to Age, HIV and Treatment. Infectious Diseases. 30:455-458. 1998
- Venous thromboembolism - Reply. New England Journal of Medicine. 337:52-53. 1997
- The Duration of Oral Anticoagulant Therapy after a Second Episode of Venous Thromboembolism. New England Journal of Medicine. 336:393-398. 1997
- A Multicenter Study of Recombinant Factor VIII (RecombinateTM) in Previously Treated Patients with Hemophilia A. Thrombosis and Haemostasis. 77:660-667. 1997
- Coagulation factor concentrates by continuous infusion. Transfusion Medicine Reviews. 11:56-63. 1997
- Multifocal pseudotumour in a single limb. Haemophilia. 3:50-53. 1997
- Optimal Duration of Oral Anticoagulant Therapy in Venous Thromboembolism. Thrombosis and Haemostasis. 78:693-698. 1997
- Anticoagulation in venous Thrombosis. Journal of the Royal Society of Medicine. 89:624-630. 1996
- Continuous infusion instead of bolus injections of factor concentrate?. Haemophilia. 2:189-191. 1996
- Home therapy with continuous infusion of factor VIII after minor surgery or serious haemorrhage. Haemophilia. 2:207-210. 1996
- Increased fetal loss in women with heritable thrombophilia. The Lancet. 348:913-916. 1996
- Multiple Joint Procedures in a Single Operative Session on Hemophilic Patients. Clinical Orthopaedics and Related Research. 328:60-64. 1996
- Pharmacokinetic properties of two factor VIII concentrates with single and double viral inactivation. Haemophilia. 2:160-165. 1996
- Role of Fibrin Sealants in Surgical Procedures on Patients With Hemostatic Disorders. Clinical Orthopaedics and Related Research. 328:65-75. 1996
- The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Duration of Anticoagulation (DURAC) Trial Study Group.. Thrombosis and Haemostasis. 75:607-611. 1996
- Cyclosporine Therapy for Acquired Factor VIII Inhibitor in a Patient with Systemic Lupus Erythematosus. Thrombosis and Haemostasis. 76:344-346. 1996
- Feasibility of Using Recombinant Factor VIIa in Continuous Infusion. Thrombosis and Haemostasis. 75:432-436. 1996
- The Significance of Hypofibrinolysis for the Risk of Recurrence of Venous Thromboembolism. Thrombosis and Haemostasis. 75:607-611. 1996
- The fixed flexed and subluxed knee in the haemophilic child: what should be done?. Haemophilia. 2:47-50. 1996
- DURATION OF ANTICOAGULANT-THERAPY FOR VENOUS THROMBOSIS - REPLY. New England Journal of Medicine. 333:1289-1289. 1995
- A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism. New England Journal of Medicine. 332:1661-1665. 1995
- Hepatitis E virus infection in hemophiliacs. Journal of Medical Virology. 46:153-156. 1995
- Influence of changes in lifestyle on fibrinolytic parameters and recurrence rate in patients with venous thromboembolism. Blood Coagulation and Fibrinolysis. 6:311-316. 1995
- The feasibility of using concentrates containing factor IX for continuous infusion. Haemophilia. 1:103-110. 1995
- [Increased risk of thrombosis in FXII deficiency?].. Lakartidningen. 92:425. 1995
- Social Support and the Development of Immune Function in Human Immunodeficiency Virus Infection. Psychosomatic Medicine. 57:32-36. 1995
- Partial expression of GP Ib measured by flow cytometry in two patients with Bernard-Soulier syndrome. Thrombosis Research. 76:441-450. 1994
- Quality of oral anticoagulant control and treatment in Sweden. Journal of Internal Medicine. 236:143-152. 1994
- Quality of oral anticoagulant control and treatment in Sweden. Duration of Anticoagulation (DURAC) Trial Study Group.. Journal of Internal Medicine. 236:143-152. 1994
- Stability of factor VIII concentrates after reconstitution. American Journal of Hematology. 45:217-223. 1994
- Coping Style in Relation to the Consumption of Factor Concentrate in HIV-Infected Hemophiliacs during the Years after Their Infection Became Known. Psychotherapy and Psychosomatics. 61:205-210. 1994
- High Versus Ultra-high Purity Factor VIII Concentrate Therapy: Prospective Evaluation of Immunological and Clinical Parameters in HIV Seronegative and Seropositive Hemophiliacs. Thrombosis and Haemostasis. 72:359-362. 1994
- Monoclonal Purified F VIII for Continuous Infusion: Stability, Microbiological Safety and Clinical Experience. Thrombosis and Haemostasis. 72:403-407. 1994
- Psychosocial Self-Prognosis in Relation to Mortality and Morbidity in Hemophiliacs with HIV Infection. Psychotherapy and Psychosomatics. 62:185-192. 1994
- Recombinant Factor VIIa in Multiple Surgery. Thrombosis and Haemostasis. 71:154-154. 1994
- Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. British Journal of Haematology. 82:729-734. 1992
- [Desmopressin--an effective agent in many hemorrhagic disorders].. Lakartidningen. 89:4155-4158. 1992
- 2 DIFFERENT MISSENSE MUTATIONS AT ARG 178 OF THE PROTEIN-C (PROC) GENE CAUSING RECURRENT VENOUS THROMBOSIS. Human Genetics. 89:685-686. 1992
- Transmission of hepatitis C with pasteurised factor VIII. The Lancet. 340:305-306. 1992
- Two different missense mutations at Arg 178 of the protein C (PROC) gene causing recurrent venous thrombosis. Human Genetics. 89:685-686. 1992
- [New preparations for coagulation disorders].. Lakartidningen. 89:2430. 1992
- A therapeutic alternative for haemophiliacs with inhibitors. Acta Paediatrica, International Journal of Paediatrics. 81:564-565. 1992
- Antithrombin-III-Stockholm: a codon 392 (Gly----Asp) mutation with normal heparin binding and impaired serine protease reactivity. Blood. 79:1428-1434. 1992
- Protein C deficiency and thromboembolism: recurrent mutation at Arg 306 in the protein C gene. Human Genetics. 88:586-588. 1992
- Hemophilia in the 1990s: Principles of Management and Improved Access to Care. Seminars in Thrombosis and Hemostasis. 18:1-10. 1992
- Treatment of Venous Thromboembolism in Patients with Congenital Deficiency of Antithrombin III. Thrombosis and Haemostasis. 68:634-636. 1992
- Haemophilia in the 1990s: Report of a Joint Meeting of the World Health Organization and World Federation of Hemophilia. Vox Sanguinis. 61:221-224. 1991
- Hypercoagulable state and thromboembolism following warfarin withdrawal in post-myocardial-infarction patients. European Heart Journal. 12:1225-1233. 1991
- Effects of factor VIII concentrates on the immune system in hemophilic patients. Annals of Hematology. 63:145-151. 1991
- A molecular genetic study of factor XI deficiency. Blood. 77:1942-1948. 1991
- DDAVP—The Multipotent Drug in Patients With Coagulopathies. Transfusion Medicine Reviews. 5:132-144. 1991
- Heparin, DDAVP and the Bleeding Time. Thrombosis and Haemostasis. 65:242-244. 1991
- Thrombotic Complications after Substitution with a FVII Concentrate. Thrombosis and Haemostasis. 66:619-619. 1991
- Antibodies against Hepatitis C in a Population of Swedish Haemophiliacs and Heterosexual Partners. Infectious Diseases. 22:393-397. 1990
- Oral surgery in patients with hereditary bleeding disorders. International Journal of Oral and Maxillofacial Surgery. 18:320-322. 1989
- INTERACTION OF IBUPROFEN AND WARFARIN ON PRIMARY HEMOSTASIS - REPLY. British Journal of Rheumatology. 28:266-266. 1989
- [Difficulties in obtaining financial support for studies of hemorrhage during treatment with anticoagulants].. Lakartidningen. 86:1354. 1989
- [Elimination of antibodies against coagulation factor VIII: Factor VIIa is the most promising therapeutic alternative].. Lakartidningen. 86:219-221. 1989
- Acute Effects with Reference to Thrombogenicity and Liver Toxicity after Injection of Different Coagulation Factor Concentrates. Pathophysiology of Haemostasis and Thrombosis: international journal on haemostasis and thrombosis research. 19:152-159. 1989
- INTERACTION OF IBUPROFEN AND WARFARIN ON PRIMARY HAEMOSTASIS. Rheumatology. 28:46-49. 1989
- HIV‐serology and lymphocyte subsets in relation to therapy and clinical development in haemophiliacs. European Journal of Haematology. 41:459-466. 1988
- Pulmonary Hypertension in Hemophilia. ACP journal club. 109:759-759. 1988
- SUCCESSFUL USE OF RECOMBINANT FACTOR VIIa IN PATIENT WITH SEVERE HAEMOPHILIA A DURING SYNOVECTOMY. The Lancet. 332:1193-1193. 1988
- Incidence of symptoms and AIDS in 146 Swedish haemophiliacs and blood transfusion recipients infected with human immunodeficiency virus.. The BMJ. 297:99-102. 1988
- HIV isolation and antigen detection in infected individuals and their seronegative sexual partners. AIDS. 2:107-112. 1988
- Haemorrhagic and Thromboembolic Complications versus Intensity of Treatment of Venous Thromboembolism with Oral Anticoagulants. Journal of Internal Medicine. 224:425-430. 1988
- Haemorrhagic and thromboembolic complications versus intensity of treatment of venous thromboembolism with oral anticoagulants.. Acta Medica Scandinavica. 224:425-430. 1988
- No Evidence for Vertical Transmission in Children Born to HIV Seropositive Male Haemophiliacs. Infectious Diseases. 20:141-143. 1988
- Immunoglobulin levels in haemophiliacs at HIV seroconversion and during follow up. Infection. 15:248-252. 1987
- FALSE NEGATIVE RESULT BY THE WELLCOZYME ANTI-HIV ASSAY IN TESTING AN HIV POSITIVE HAEMOPHILIAC. The Lancet. 329:1200-1201. 1987
- [Hereditary thrombogenic defects in the national family registry].. Lakartidningen. 84:1251-1253. 1987
- Ddavp-induced correction of prolonged bleeding time in patients with congenital platelet function defects. Thrombosis Research. 45:165-174. 1987
- HIV Infection in a Defined Population of Swedish Haemophiliacs. Infectious Diseases. 19:159-166. 1987
- Plasmodium berghei sporozoite invasion is blocked in vitro by sporozoite-immobilizing antibodies. Infection and Immunity. 51:859-864. 1986
- Long‐term Sequelae of Calf Vein Thrombosis Treated with Heparin or Low‐dose Streptokinase. Journal of Internal Medicine. 219:349-357. 1986
- Transmission of HIV Infection to Heterosexual Partners but Not to Household Contacts of Seropositive Haemophiliacs. Infectious Diseases. 18:497-500. 1986
- Thrombolysis and fibrinolytic parameters during heparin treatment of deep vein thrombosis. Thrombosis Research. 39:607-612. 1985
- Factors and inhibitors of blood coagulation and fibrinolysis in acute nonlymphoblastic leukaemia. European Journal of Haematology. 34:332-339. 1985
- The Duration of Oral Anticoagulation after Deep Vein Thrombosis. Journal of Internal Medicine. 217:547-552. 1985
- Relationship Between Thromboembolic Complications and Intensity of Treatment During Long-Term Prophylaxis with Oral Anticoagulants Following DVT. Thrombosis and Haemostasis. 53:137-140. 1985
- Studies on the medical treatment of deep vein thrombosis.. Journal of Internal Medicine, Supplement. 704:1-68. 1985
- WRIGHT'S b DETERMINANT, MONOCLONAL ANTIBODIES, AND PLASMODIUM FALCIPARUM MEROZOITE INVASION. The Lancet. 324:934-935. 1984
- Local venous infusion of streptokinase in DVT. Thrombosis Research. 34:213-216. 1984
- A Comparative Randomized Trial of Low-Dose Versus High-Dose Streptokinase in Deep Vein Thrombosis of the Thigh. Thrombosis and Haemostasis. 51:261-265. 1984
- Hepatitis, Epidemiology and Liver Function in Hemophiliacs in Sweden. Journal of Internal Medicine. 215:249-256. 1984
- Intensive Initial Oral Anticoagulation and Shorter Heparin Treatment in Deep Vein Thrombosis. Thrombosis and Haemostasis. 52:276-280. 1984
- Thermography in the Diagnosis of DVT. Thrombosis and Haemostasis. 46:652-654. 1981